Session 4 – Clinical Lipidomics – Current Applications


Plasma ceramides as biomarkers of cerebrovascular disease and dementia

Michelle M. Mielke, Ph.D. received a Bachelor’s of Science in Neuroscience at the University of Pittsburgh and a doctorate in Psychiatric Epidemiology from the Johns Hopkins University Bloomberg School of Public Health. She is currently a Professor of Epidemiology and of Neurology at the Mayo Clinic. She is also the Associate Chair of Faculty Development and Academic Affairs in the Department of Quantitative Health Sciences.

Dr. Mielke works as a translational epidemiologist to further understanding of the etiology and epidemiology of neurodegenerative diseases. One focus of her research is the identification of fluid biomarkers for the diagnosis, prediction, and progression of Alzheimer's disease and related diseases. Her work, in both CSF and blood, has emphasized the utility of sphingolipids, phosphorylated tau, neurofilament light, and inflammatory markers. She is past chair of the Biofluid-Based Biomarker Professional Interest Area under the Alzheimer’s Association.

Another focus of Dr. Mielke’s research is on understanding sex and gender differences in the development and progression of Alzheimer’s disease and of other aging-related conditions. She directs the Mayo Clinic Specialized Center of Research Excellence (SCORE) on Sex Differences. She is the PI of several NIH- and Foundation-funded clinical- and epidemiological-based grants and has published over 330 manuscripts.